NCT04224064 Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas
| NCT ID | NCT04224064 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut du Cancer de Montpellier - Val d'Aurelle |
| Condition | Liposarcoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 158 participants |
| Start Date | 2020-08-26 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 158 participants in total. It began in 2020-08-26 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH.
Eligibility Criteria
Inclusion Criteria for LPS patients cohort: Men/women older than 18 years old, Surgery for : * Localized WD-LPS and DD-LPS, and/or * WD-LPS or DD-LPS local relapse, and/or * WD-LPS or DD-LPS distant relapse and/or * Deep adipocytic tumor greater than 5 cms, suggestive of atypical lipomatous tumor Patient accepting blood sample, Patient who signed informed consent Inclusion Criteria for healthy subjects cohort: Men/women older than 18 years old, Accepting blood sample, Who signed informed consent Matching on sex and age on LPS patient cohort Exclusion Criteria: Presence of NeoAdjuvant Treatment for the present cancer, Unaffiliated patient to French Social Protection System, Patient whose follow up is impossible for psychologic, social, geographic, familial reasons Psychiatric illness that would prevent the patient from giving informed consent or being compliant with the study procedures Patient who have another cancer within the 5 years of the inclusion except in situ breast carcinoma, in situ, basocellular carcinoma. Pregnancy and/or feeding
Contact & Investigator
Nelly FIRMIN, MD
STUDY CHAIR
Institut Régional du Cancer de Montpellier (ICM)
Frequently Asked Questions
Who can join the NCT04224064 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Liposarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04224064 currently recruiting?
Yes, NCT04224064 is actively recruiting participants. Contact the research team at DRCI-icm105@icm.unicancer.fr for enrollment information.
Where is the NCT04224064 trial being conducted?
This trial is being conducted at Montpellier, France.
Who is sponsoring the NCT04224064 clinical trial?
NCT04224064 is sponsored by Institut du Cancer de Montpellier - Val d'Aurelle. The principal investigator is Nelly FIRMIN, MD at Institut Régional du Cancer de Montpellier (ICM). The trial plans to enroll 158 participants.